ARTICLE | Clinical News
AJM300: Phase IIa data
May 19, 2014 7:00 AM UTC
A double-blind, Japanese Phase IIa trial in 102 patients with moderately active UC who had an inadequate response or intolerance to 5-aminosalicylic acid agents or steroids showed that thrice-daily 96...